Tratamiento con rituximab en un paciente con glomerulonefritis p-ANCA, hemorragia alveolar y múltiples recidivas en hemodiálisis
Treatment with rituximab for a patient with p-ANCA glomerulonephritis, alveolar bleeding and multiple relapses during haemodialysis
Leído
17324
Vecesse ha leído el artículo
3279
Total PDF
14045
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 10 | 136 | 40 | 176 |
| 2025 9 | 165 | 33 | 198 |
| 2025 8 | 215 | 52 | 267 |
| 2025 7 | 132 | 16 | 148 |
| 2025 6 | 227 | 96 | 323 |
| 2025 5 | 136 | 114 | 250 |
| 2025 4 | 168 | 24 | 192 |
| 2025 3 | 214 | 47 | 261 |
| 2025 2 | 222 | 26 | 248 |
| 2025 1 | 203 | 42 | 245 |
| 2024 12 | 168 | 27 | 195 |
| 2024 11 | 189 | 56 | 245 |
| 2024 10 | 260 | 32 | 292 |
| 2024 9 | 188 | 25 | 213 |
| 2024 8 | 230 | 56 | 286 |
| 2024 7 | 184 | 32 | 216 |
| 2024 6 | 190 | 36 | 226 |
| 2024 5 | 191 | 45 | 236 |
| 2024 4 | 167 | 39 | 206 |
| 2024 3 | 181 | 29 | 210 |
| 2024 2 | 141 | 33 | 174 |
| 2024 1 | 163 | 40 | 203 |
| 2023 12 | 145 | 32 | 177 |
| 2023 11 | 143 | 30 | 173 |
| 2023 10 | 167 | 43 | 210 |
| 2023 9 | 172 | 45 | 217 |
| 2023 8 | 157 | 15 | 172 |
| 2023 7 | 188 | 27 | 215 |
| 2023 6 | 150 | 22 | 172 |
| 2023 5 | 162 | 35 | 197 |
| 2023 4 | 125 | 24 | 149 |
| 2023 3 | 109 | 26 | 135 |
| 2023 2 | 125 | 34 | 159 |
| 2022 1 | 113 | 31 | 144 |
| 2022 12 | 94 | 34 | 128 |
| 2022 11 | 117 | 41 | 158 |
| 2022 10 | 117 | 41 | 158 |
| 2022 9 | 105 | 33 | 138 |
| 2022 8 | 122 | 44 | 166 |
| 2022 7 | 105 | 58 | 163 |
| 2022 6 | 83 | 46 | 129 |
| 2022 5 | 92 | 41 | 133 |
| 2022 4 | 105 | 63 | 168 |
| 2022 3 | 93 | 50 | 143 |
| 2022 2 | 75 | 55 | 130 |
| 2021 1 | 83 | 62 | 145 |
| 2021 12 | 100 | 52 | 152 |
| 2021 11 | 100 | 54 | 154 |
| 2021 10 | 96 | 46 | 142 |
| 2021 9 | 94 | 36 | 130 |
| 2021 8 | 92 | 44 | 136 |
| 2021 7 | 88 | 36 | 124 |
| 2021 6 | 78 | 23 | 101 |
| 2021 5 | 81 | 38 | 119 |
| 2021 4 | 172 | 78 | 250 |
| 2021 3 | 102 | 47 | 149 |
| 2021 2 | 86 | 36 | 122 |
| 2020 1 | 87 | 28 | 115 |
| 2020 12 | 69 | 23 | 92 |
| 2020 11 | 103 | 13 | 116 |
| 2020 10 | 76 | 21 | 97 |
| 2020 9 | 74 | 15 | 89 |
| 2020 8 | 79 | 12 | 91 |
| 2020 7 | 74 | 24 | 98 |
| 2020 6 | 79 | 15 | 94 |
| 2020 5 | 88 | 20 | 108 |
| 2020 4 | 48 | 28 | 76 |
| 2020 3 | 61 | 22 | 83 |
| 2020 2 | 83 | 28 | 111 |
| 2020 1 | 83 | 24 | 107 |
| 2019 12 | 78 | 26 | 104 |
| 2019 11 | 74 | 28 | 102 |
| 2019 10 | 81 | 31 | 112 |
| 2019 9 | 87 | 27 | 114 |
| 2019 8 | 83 | 30 | 113 |
| 2019 7 | 105 | 26 | 131 |
| 2019 6 | 83 | 25 | 108 |
| 2019 5 | 75 | 18 | 93 |
| 2019 4 | 82 | 50 | 132 |
| 2019 3 | 46 | 23 | 69 |
| 2019 2 | 39 | 27 | 66 |
| 2019 1 | 46 | 21 | 67 |
| 2018 12 | 116 | 44 | 160 |
| 2018 11 | 122 | 13 | 135 |
| 2018 10 | 99 | 18 | 117 |
| 2018 9 | 86 | 10 | 96 |
| 2018 8 | 67 | 11 | 78 |
| 2018 7 | 82 | 21 | 103 |
| 2018 6 | 87 | 17 | 104 |
| 2018 5 | 94 | 13 | 107 |
| 2018 4 | 69 | 14 | 83 |
| 2018 3 | 74 | 6 | 80 |
| 2018 2 | 78 | 7 | 85 |
| 2018 1 | 50 | 11 | 61 |
| 2017 12 | 62 | 4 | 66 |
| 2017 11 | 42 | 8 | 50 |
| 2017 10 | 40 | 8 | 48 |
| 2017 9 | 53 | 11 | 64 |
| 2017 8 | 35 | 10 | 45 |
| 2017 7 | 44 | 3 | 47 |
| 2017 6 | 43 | 10 | 53 |
| 2017 5 | 49 | 9 | 58 |
| 2017 4 | 43 | 5 | 48 |
| 2017 3 | 39 | 3 | 42 |
| 2017 2 | 29 | 6 | 35 |
| 2016 1 | 31 | 4 | 35 |
| 2016 12 | 73 | 8 | 81 |
| 2016 11 | 97 | 13 | 110 |
| 2016 10 | 130 | 10 | 140 |
| 2016 9 | 149 | 4 | 153 |
| 2016 8 | 290 | 7 | 297 |
| 2016 7 | 225 | 4 | 229 |
| 2016 6 | 131 | 0 | 131 |
| 2016 5 | 156 | 0 | 156 |
| 2016 4 | 111 | 0 | 111 |
| 2016 3 | 107 | 0 | 107 |
| 2016 2 | 123 | 0 | 123 |
| 2015 1 | 130 | 0 | 130 |
| 2015 12 | 146 | 0 | 146 |
| 2015 11 | 125 | 0 | 125 |
| 2015 10 | 120 | 0 | 120 |
| 2015 9 | 80 | 0 | 80 |
| 2015 8 | 87 | 0 | 87 |
| 2015 7 | 87 | 0 | 87 |
| 2015 6 | 46 | 0 | 46 |
| 2015 5 | 80 | 0 | 80 |
| 2015 4 | 29 | 0 | 29 |
Mostrar todo
